Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS)
Objective The objective of this article is to evaluate near-infrared spectroscopy (NIRS), a non-invasive technique to assess tissue oxygenation and mitochondrial function, as a diagnostic tool for statin-associated muscle symptoms (SAMS).Methods We verified SAMS in 39 statin-treated patients (23 wom...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-02-01
|
| Series: | Open Heart |
| Online Access: | https://openheart.bmj.com/content/11/1/e002551.full |
| _version_ | 1797299881526689792 |
|---|---|
| author | Paul D Thompson Laura A. Mangone Beth A. Taylor Robert Schmelzer Sung Gi Noh Michael C White Oh Sung Kwon |
| author_facet | Paul D Thompson Laura A. Mangone Beth A. Taylor Robert Schmelzer Sung Gi Noh Michael C White Oh Sung Kwon |
| author_sort | Paul D Thompson |
| collection | DOAJ |
| description | Objective The objective of this article is to evaluate near-infrared spectroscopy (NIRS), a non-invasive technique to assess tissue oxygenation and mitochondrial function, as a diagnostic tool for statin-associated muscle symptoms (SAMS).Methods We verified SAMS in 39 statin-treated patients (23 women) using a double-blind, placebo-controlled, cross-over protocol. Subjects with suspected SAMS were randomised to simvastatin 20 mg/day or placebo for 8 weeks, followed by a 4-week no treatment period and then assigned to the alternative treatment, either simvastatin or placebo. Tissue oxygenation was measured before and after each statin or placebo treatment using NIRS during handgrip exercise at increasing intensities of maximal voluntary contraction (MVC).Results 44% (n=17) of patients were confirmed as having SAMS (11 women) because they reported discomfort only during simvastatin treatment. There were no significant differences in percent change in tissue oxygenation in placebo versus statin at all % MVCs in all subjects. The percent change in tissue oxygenation also did not differ significantly between confirmed and unconfirmed SAMS subjects on statin (−2.4% vs −2.4%, respectively) or placebo treatment (−1.1% vs −9%, respectively). The percent change in tissue oxygenation was reduced after placebo therapy in unconfirmed SAMS subjects (−10.2%) (p≤0.01) suggesting potential measurement variability.Conclusions NIRS in the forearm cannot differentiate between confirmed and unconfirmed SAMS, but further research is needed to assess the usability of NIRS as a diagnostic tool for SAMS.Trial registration number NCT03653663. |
| first_indexed | 2024-03-07T22:58:06Z |
| format | Article |
| id | doaj.art-43f8d0ec1f5f4d6a99469a6d0e0ab633 |
| institution | Directory Open Access Journal |
| issn | 2053-3624 |
| language | English |
| last_indexed | 2024-03-07T22:58:06Z |
| publishDate | 2024-02-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Open Heart |
| spelling | doaj.art-43f8d0ec1f5f4d6a99469a6d0e0ab6332024-02-22T17:40:08ZengBMJ Publishing GroupOpen Heart2053-36242024-02-0111110.1136/openhrt-2023-002551Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS)Paul D Thompson0Laura A. Mangone1Beth A. Taylor2Robert Schmelzer3Sung Gi Noh4Michael C White5Oh Sung Kwon68Division of Cardiology, Hartford Hospital, Hartford, Connecticut, USADepartment of Kinesiology, University of Connecticut, Storrs, Connecticut, USADepartment of Kinesiology, University of Connecticut, Storrs, Connecticut, USADepartment of Kinesiology, University of Connecticut, Storrs, Connecticut, USADepartment of Kinesiology, University of Connecticut, Storrs, Connecticut, USASchool of Pharmacy, University of Connecticut, Storrs, Connecticut, USADepartment of Kinesiology, University of Connecticut, Storrs, Connecticut, USAObjective The objective of this article is to evaluate near-infrared spectroscopy (NIRS), a non-invasive technique to assess tissue oxygenation and mitochondrial function, as a diagnostic tool for statin-associated muscle symptoms (SAMS).Methods We verified SAMS in 39 statin-treated patients (23 women) using a double-blind, placebo-controlled, cross-over protocol. Subjects with suspected SAMS were randomised to simvastatin 20 mg/day or placebo for 8 weeks, followed by a 4-week no treatment period and then assigned to the alternative treatment, either simvastatin or placebo. Tissue oxygenation was measured before and after each statin or placebo treatment using NIRS during handgrip exercise at increasing intensities of maximal voluntary contraction (MVC).Results 44% (n=17) of patients were confirmed as having SAMS (11 women) because they reported discomfort only during simvastatin treatment. There were no significant differences in percent change in tissue oxygenation in placebo versus statin at all % MVCs in all subjects. The percent change in tissue oxygenation also did not differ significantly between confirmed and unconfirmed SAMS subjects on statin (−2.4% vs −2.4%, respectively) or placebo treatment (−1.1% vs −9%, respectively). The percent change in tissue oxygenation was reduced after placebo therapy in unconfirmed SAMS subjects (−10.2%) (p≤0.01) suggesting potential measurement variability.Conclusions NIRS in the forearm cannot differentiate between confirmed and unconfirmed SAMS, but further research is needed to assess the usability of NIRS as a diagnostic tool for SAMS.Trial registration number NCT03653663.https://openheart.bmj.com/content/11/1/e002551.full |
| spellingShingle | Paul D Thompson Laura A. Mangone Beth A. Taylor Robert Schmelzer Sung Gi Noh Michael C White Oh Sung Kwon Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS) Open Heart |
| title | Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS) |
| title_full | Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS) |
| title_fullStr | Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS) |
| title_full_unstemmed | Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS) |
| title_short | Skeletal muscle mitochondrial capacity in patients with statin-associated muscle symptoms (SAMS) |
| title_sort | skeletal muscle mitochondrial capacity in patients with statin associated muscle symptoms sams |
| url | https://openheart.bmj.com/content/11/1/e002551.full |
| work_keys_str_mv | AT pauldthompson skeletalmusclemitochondrialcapacityinpatientswithstatinassociatedmusclesymptomssams AT lauraamangone skeletalmusclemitochondrialcapacityinpatientswithstatinassociatedmusclesymptomssams AT bethataylor skeletalmusclemitochondrialcapacityinpatientswithstatinassociatedmusclesymptomssams AT robertschmelzer skeletalmusclemitochondrialcapacityinpatientswithstatinassociatedmusclesymptomssams AT sungginoh skeletalmusclemitochondrialcapacityinpatientswithstatinassociatedmusclesymptomssams AT michaelcwhite skeletalmusclemitochondrialcapacityinpatientswithstatinassociatedmusclesymptomssams AT ohsungkwon skeletalmusclemitochondrialcapacityinpatientswithstatinassociatedmusclesymptomssams |